CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Exclusion Criteria

• •Local, locally-advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography \[CT\], magnetic resonance imaging \[MRI\])
• •Measurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesion
• •No evidence of biliary duct obstruction, unless obstruction is controlled by local treatment or, in whom the biliary tree can be decompressed by endoscopic or percutaneous stenting with subsequent reduction in bilirubin to below 1.5 x upper level of normal (ULN)
• •No acute toxic effects from previous treatment superior to grade 1 at the start of the study
• •Eastern Cooperative Oncology Group (ECOG) performance status being 0-3
• •Expected survival \> 3 months
• •Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device \[IUD\], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation
• •Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists
• •Granulocyte count \>= 1500/mm\^3
• •White blood cell (WBC) \>= 3500 cells/mm\^3 or \>= 3.5 bil/L
• +28 more criteria